Palexia Depot (Tapentadol Hydrochloride)

Tapentadol Hydrochloride, the active ingredient in Palexia Depot, is an opioid analgesic presented as a depot formulation for prolonged subcutaneous injection use. It is indicated for the management of moderate to severe chronic pain in adult patients who require continuous opioid therapy.

GNH USA supplies Palexia Depot as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Palexia Depot is an opioid analgesic that acts within the central nervous system to alleviate pain associated with several conditions. - Chronic cancer‑related pain: provides long‑lasting relief for patients with persistent tumor‑related discomfort. - Severe postoperative pain: maintains analgesia when oral opioids are insufficient or not tolerated. - Chronic non‑cancer pain: offers continuous opioid coverage for conditions such as neuropathic pain when other treatments have failed.

Adverse reactions to Palexia Depot can vary in frequency and severity.

Common Side Effects: - Nausea: mild to moderate upset stomach feeling. - Constipation: reduced bowel movements or difficulty passing stool. - Dizziness: light‑headedness or feeling unsteady. - Somnolence: increased sleepiness or fatigue. - Headache: mild to moderate head pain. - Dry mouth: reduced salivation leading to a dry oral cavity.

Serious or Rare Side Effects: - Respiratory depression: slowed or shallow breathing that may be life‑threatening. - Severe hypotension: marked drop in blood pressure causing dizziness or fainting. - Seizures: convulsive episodes, particularly in patients with a seizure history. - Allergic reactions: rash, itching, swelling, or anaphylaxis. - Opioid use disorder: risk of dependence, tolerance, or misuse. - adrenal insufficiency: abnormal cortisol production affecting stress response.

When prescribing Palexia Depot, clinicians should consider several safety aspects. - Assess patient history: evaluate the risk for opioid misuse and addiction. - Monitor respiratory function: watch for signs of depressed breathing especially during dose initiation. - Evaluate renal and hepatic function: dose adjustments may be needed in impairment. - Avoid concurrent CNS depressants: increased risk of sedation and respiratory depression. - Educate patients on proper use: emphasize the importance of adherence and storage instructions. - Store at below 25°C: keep in the original packaging, protect from moisture and light.

Palexia ​​​​​​   ​  ​  ​  ​   ​    ​    ​     ​  ​  ​   ​    ​  ​  ​    ​  ​ ‑  ​    ​

Major Interactions (Avoid): - Concomitant ​ ​ ​  ​   ​  ​  ​  ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​​ - MAO‑inhibitors: may cause hypertensive crisis. - Benzodiazepines: additive CNS depression. - CNS depressants (alcohol, barbiturates): heightened sedation and respiratory risk. - CYP3A4 inhibitors (e.g., ketoconazole): increased tapentadol plasma levels. - CYP2D6 inhibitors (e.g., fluoxetine): reduced analgesic conversion.

Moderate Interactions (Monitor Closely): -           ... -  ... ...